Prot #CYNK-001-GBM-002: A Phase I/IIa Open Label, Multicenter, Non- Randomized, Trial to Assess the Safety and Efficacy of CYNK-001 in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild Type Glioblastoma

Project: Research project

Project Details

Effective start/end date9/7/229/7/25


  • CTI Clinical Trial and Consulting Services (Prot #CYNK-001-GBM-002)
  • Celularity Inc (Prot #CYNK-001-GBM-002)